Immunization Products Limited
Executive Summary
Elizabeth Corsi appointed VP and general manager of the newly- formed operational unit for the Rhone-Poulenc Rorer/Immune Response Corp. joint venture for an AIDS vaccine. Results of Phase II/III trials of the AIDS immunotherapeutic (the "Salk vaccine") are now being compiled and should be unblinded by early next year. A PLA will be filed in 1993 if the results are positive. Production capacities are being scaled up for commercial production of the vaccine.